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PKANicotinamide (NAM) is the amide of nicotinic acid and a predominant precursor for NAD+ biosynthesis via the
salvage pathway. Sirt1 is a NAD+-dependent deacetylase, playing an important role in regulating cellular func-
tions. Although hepatoprotective effect of NAM has been reported, the underlying mechanism remains elusive.
ER stress, induced by saturated fatty acids, in speciﬁc palmitate, plays a pathological role in the development of
nonalcoholic fatty liver disease. This study aims to determine the effect of NAM on palmitate-induced ER stress
in hepatocytes and to elucidatemolecularmechanismsbehind. BothHepG2 cells and primarymouse hepatocytes
were exposed to palmitate (conjugated to BSA at a 2:1 M ratio), NAM, or their combination for different dura-
tions. Cellular NAD+ level, Sirt1 expression/activity, ER stress, as well as cAMP/PKA/CREB pathway activation
were determined. NAM increased Sirt1 expression and enzymatic activity, which contributes to the ameliorative
effect of NAMon palmitate-triggered ER stress. NAM increased intracellular NAD+ level in hepatocytes, however,
blocking the salvage pathway, a pathway for NAD+ synthesis fromNAM, only partially prevented NAM-induced
Sirt1 upregulation while completely prevented NAD+ increase in response to NAM. Further mechanistic investi-
gations revealed that NAM elevated intracellular cAMP level via suppressing PDE activity, leading to downstream
PKA and CREB activation. Importantly, cAMP/PKA/CREB pathway blockade abolished not only NAM-induced
Sirt1 upregulation, but also its protective effect against ER stress. Our results demonstrate that NAM protects he-
patocytes against palmitate-induced ER stress in hepatocytes via upregulating Sirt1. Activation of the cAMP/PKA/
CREB pathway plays a key role in NAM-induced Sirt1 upregulation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Lipotoxicity, the cellular dysfunction or cell death induced by lipid
accumulation in cell types other than adipocytes, plays a pathological
role in the development of obesity-related non-alcoholic fatty liver dis-
ease (NAFLD) [1]. Palmitate, a 16-C saturated fatty acid, is one of the
most abundant free fatty acids (FFAs) in the circulation and a major in-
ducer of lipotoxicity in hepatocytes [2]. ER stress plays a mechanistic
role in palmitate-induced cellular dysfunction in hepatocytes, including
cell death and insulin resistance (IR) [3]. Sirt1 is a NAD+-dependent
deacetylase catalyzing the deacetylation of protein targets at a speciﬁce A; CREB, cyclic AMP response-
bosyltransferase; NMN, nicotin-
n this study declare that they do
t of interest with respect to this
y and Nutrition, University of
, IL 60612, USA.lysine residue by hydrolyzingNAD+ to produce a de-acetylated protein,
acetyl-ADP-ribose, and nicotinamide (NAM) [4,5]. It plays an important
role in regulating cellular functions via modifying acetylation status of a
wide range ofmolecules, including enzymes, histones, and transcriptional
regulators [6]. Impaired hepatic Sirt1 signaling contributes to the patho-
genesis of both alcoholic liver disease and NAFLD [7–11]. Sirt1 activation
has been reported to protect hepatocytes against palmitate-triggered ER
stress [12].
Intracellular NAD+ content plays a key role in controlling Sirt1
expression and activity. The biosynthesis of NAD+ in mammalian cells
occurs through two major pathways: a de novo pathway and a salvage
pathway [13,14]. The de novo pathway (the Preiss–Handler pathway)
utilizes tryptophan to generate NAD+ through kynurenine pathway,
while the salvage pathway regenerates NAD+ from nicotinic acid,
NAM, or NAM riboside present in the metabolites of NAD+ or dietary
sources. In mammalian cells, most NAD+ is synthesized by the salvage
pathway from NAM [4,5]. The ﬂuctuation in NAD+ availability in re-
sponse to either energy status change or changes in NAD+ biosynthetic
or degradation process leads to altered Sirt1 expression and activity. The
increase of cellular NAD+ level derived from either low energy condi-
tions, such as fasting, caloric restriction, and exercise, or enzymatic
2930 J. Li et al. / Biochimica et Biophysica Acta 1853 (2015) 2929–2936activation of NAMphosphoribosyltransferase (Nampt), the rate limiting
enzyme for NAD+ biosynthesis from NAM via the salvage pathway,
upregulates Sirt1 activity [15–21]. By contrast, high-energy diet con-
sumption reduces cellular NAD+ concentration, leading to suppressed
Sirt1 activation [22–24].
Other than well-documented canonical mechanism of modulating
cellular NAD+ level to regulate Sirt1, accumulating evidence supports
that Sirt1 activity is also regulated at expression level, which is NAD+-
independent. Among a growing list of transcription factors reported to
control the expression of Sirt1, cyclic AMP response-element-binding
protein (CREB), a transcription factor whose activation is mediated by
PKA in response to increased intracellular cAMP level, has recently
emerged to play a critical role in the regulation of Sirt1 expression
[25,26].
NAM is the amide of nicotinic acid (vitamin B3/niacin). It is the gen-
eral product of Sirt1-catalyzeddeacetylation reactions andwas reportedFig. 1. NAM supplementation increases Sirt1 expression and activity in hepatocytes. A & B. NAM
were treated with NAMwith indicated doses for 8 h. Sirt1 expressions at both mRNA and prote
pendent studies. * p b 0.05 vs. control. C. NAM upregulates Sirt1 expression in a dose-depende
NAM for indicated doses for 8 h. Sirt1 protein abundance was determined by Western blot. D
cells were treated with 5 mM NAM for indicated time periods. Sirt1 protein abundance were d
by FoxO1 lysine-acetylated status. Lysine acetylation of immunoprecipated FoxO1 proteinwasm
subjected toWestern blot and probed with anti-acetyl lysine to determine FoxO1 acetylation s
with different letters differ signiﬁcantly (p b 0.05).to inhibit Sirt1 enzyme activity with either competitive or noncompet-
itive mechanism [27–29]. Paradoxically, as NAM also serves as the pre-
dominant endogenous precursor for NAD+ biosynthesis via the salvage
pathway, several recent studies have demonstrated that NAM supple-
mentation in cell culture increased intracellular NAD+ level in a variety
of cell types, leading to Sirt1 activation [30,31]. Nevertheless, the effect
of NAM on Sirt1 expression and activity in hepatocytes, as well as its
role in protecting hepatocytes against harmful cellular stresses, have
not been well-established. In this study, we conducted in vitro cell
culture studies to determine these events. We demonstrated that
NAM supplementation upregulated Sirt1 expression and enzymatic
activity in hepatocytes and ameliorated ER stress induced by palmitate
exposure. Intriguingly, our mechanistic investigations revealed for the
ﬁrst time that NAM-induced Sirt1 upregulation was independent of its
NAD+-incrementing action, but involving cAMP/PKA/CREB pathway
activation.increases Sirt1 gene expression in a dose-dependent manner in HepG2 cells. HepG2 cells
in level were determined. All values are denoted asmeans ± SD from three or more inde-
nt fashion in primary mouse hepatocytes. Mouse primary hepatocytes were treated with
. Time-course changes of Sirt1 expression in response to NAM supplementation. HepG2
etermined byWestern blot. E. NAM increases Sirt1 activity. Sirt1 activity was determined
easured inHepG2 cells treatedwith orwithout NAM for 4 h. The pull-downproteinswere
tatus. All values are denoted as means± SD from three or more independent studies. Bars
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2.1. Cells culture
HepG2 cell was obtained from the American Type Culture Collection
(Manassas, VA). Primarymouse hepatocyteswere obtained fromCelsis In
Vitro Technologies (M91684). BothHepG2 cells and primary hepatocytes
were cultured in DMEM (Sigma-Aldrich, D5648) containing 10% (v/v)
fetal bovine serum, 2 mmol/l glutamine (Sigma-Aldrich, G3126),
100 U/ml penicillin, and 100 μg/ml streptomycin at 37 °C in a humidiﬁed
O2/CO2 (95:5) atmosphere. All experiments were repeated at least 3
times.2.2. Gene silencing by siRNA
Transient gene silencing was attained by transfection either scram-
bled siRNA (Control, sc-37007, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) or siRNAs for target genes (CREB: sc-29281, Sirt1: sc-40986,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) into HepG2 cells using
siPORT lipid transfection reagent according to the manufacturer's in-
structions. Gene silencingwas veriﬁed by detecting proteinwith immu-
noblotting analysis after transient transfection with siRNA.2.3. Cell lysates and Western blotting detections
Total proteins from hepatocyte were obtained using Western lysis
buffer consisting of the following: 20 mM Tris·HCl, pH 7.4, 150 mM
NaCl, 10% glycerol, 2%Nonidet P-40, 1mMEDTA, pH8.0, 20mMsodium
ﬂuoride, 30 mM sodium pyrophosphate, 0.2% sodium dodecyl sulfate,
0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl ﬂuoride,
1 mM dithiothreitol, 1 mM sodium vanadate, 50 μM leupeptin, and
5 μM aprotinin. Samples were incubated on ice with frequent vortexing
for 15min and centrifuged for 20min at 18,000g. The protein content of
each supernatant was quantiﬁed via a protein assay reagent from Bio-
Rad Laboratories (Hercules, CA) in accordance with the manufacturer's
instructions. Proteins were separated by SDS-PAGE and transferred
to 0.45 μm Immobilin-P polyvinylidene diﬂuoride membrane
(PerkinElmer Life Sciences). After transfer, membranes were blocked
in 5% (wt./vol.) nonfat dry milk in PBS-0.1% Tween 20 and probed
with anti-phospho-PKA (5566), phospho-CREB (9191s), phospho-
Perk (3179) from Cell Signaling, anti-beta-actin (sc-1615), anti-Sirt1
(sc-15,404) from Santa Cruz Biotechnology, anti-alpha-tubulin (600–
401–880) from Rockland Inc. Horseradish peroxidase conjugated
secondary antibodies and enhanced chemiluminescence substrate kit
(Thermo Scientiﬁc, IL) were used in detection of speciﬁc proteins.2.4. Quantitative real-time RT-PCR
Total RNA from hepatocytes was isolated with a phenol-chloroform
extraction. For each sample, 1.0 μg total RNA was reverse transcribed
using a high-capacity cDNA reverse transcription kit (Applied Biosystems,
Foster City, CA). The cDNAwas ampliﬁed inMicroAmpOptical 96-well re-
action plates with a SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA) on an Applied Biosystems Prism 7000 sequence detection
system. Relative gene expression was calculated after normalization by a
house-keeping gene (mouse or human 18S rRNA).Fig. 2. The effect of NAM supplementation on intracellular NAD content. HepG2 cells were
treatedwith NAM (1 and 5mM) for 2 and 8 h, respectively. Intracellular NAD+ andNADH
levels were determined. A. NAM increases cellular NAD+ concentration. B. NAM increases
cellular NAD+/NADH ratio. * p b 0.05 vs. control. All values are denoted as means ± SD
from three or more independent studies.2.5. Intracellular NAD+ Measurement
NAD+ level in cell lysate were measured using NAD/NADH quantiﬁ-
cation kit in accordancewith themanufacturer's instructions (Biovision
Inc., Milpitas, CA). All data are representative of at least three indepen-
dent experiments.2.6. Intracellular cAMP measurement
Intracellular cAMP levels in cell lysate were measured using a cAMP
enzyme immunoassay kit (Cayman Chemical, Ann Arbor, Michigan) in
accordance with the manufacturer's instructions.
2.7. Intracellular phosphodiesterase (PDE) activity assay
Hepatocytes were treated with NAM for 2 h and PDE activity was
measured using a commercially available assay kit according to the
manufacturer's instruction (ab139460, Abcam, Cambridge, MA).
2.8. Immunoprecipitation (IP)
Cell lysateswere obtained in IP buffer (150mMNaCl, 50mMTris–HCl,
1%NP-40, PH7.8, andmammalian cell speciﬁc protease inhibitor cocktail)
and adjusted to the same concentration of 1 mg/ml, then cell lysates
(200 μg protein) were incubated with primary antibody (1mg/ml) over-
night at 4 °C with constant rotation, followed by adding Protein A/G plus
Agarose (Santa Cruz Biotechnology, Santa Cruz, CA) 50 μl to incubate
for 1–2 h at 4 °C. The lysates were then centrifuged at 4000g for
1 min, the pelleted beads were then washed 4 times with IP buffer,
and immunoprecipitated proteinswere eluted from beads by preparing
1× sample forWesternblotting (12.5 μl 4× loadingbuffer, DTT 5 μl, lysis
buffer 37.5 μl). Beads with immunoprecipitated proteins were incubat-
ed at 95 °C for 5 min. After a brief centrifugation, the supernatants (im-
munoprecipitation samples) were subject to Western blotting.
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All data were expressed as Mean ± SD. Statistical analysis was
performed using a one-way ANOVA and was analyzed further by Post-
hoc test with Fisher's least signiﬁcant difference (LSD). Differences be-
tween treatments were considered to be statistically signiﬁcant at
p b 0.05.3. Results
3.1. NAM upregulates Sirt1 expression and activity in hepatocytes
The effect of NAM on Sirt1 expression was determined primarily in
HepG2 cells and key ﬁndings were validated in mouse primary hepato-
cytes. InHepG2 cells, an eight-hour exposure of NAM increased Sirt1 ex-
pression, at both mRNA and protein level, in a dose-dependent manner
(Fig. 1A & B). Similar effects were observed whenmouse primary hepa-
tocytes were used (Fig. 1C). Time-course changes of Sirt1 protein abun-
dance in response to NAM exposure in HepG2 cells were shown in
Fig. 1D. NAM markedly increased Sirt1 expression in 2 h, and this in-
crease was maintained throughout the 16 h of the investigation. The ef-
fect of NAM on Sirt1 enzymatic activity was determined via detecting
the effect of NAM on acetylation status of FOXO1, a well-established
substrate of Sirt1-catalyzed deacetylation reaction. Immunoprecipita-
tion result showed that, in comparison to control cells, HepG2 cells
exposed to NAM for 4 hmanifested an evident decrease in lysine acety-
lation level of FoxO1 (Fig. 1E).Fig. 3. Increase in intracellular NAD+ level partially contributes to NAM-induced Sirt1 upregula
with either FK866, a speciﬁc inhibitor of Nampt, or NMN, a direct product of Nampt-catalyzed r
as the precursor, and the salvage pathway, which utilizes NAM as the precursor, for NAD+ bi
salvage pathway. B. The inhibition of Nampt via FK866 prevents NAM-induced NAD+ increase
Sirt1 upregulation. All values are denoted as means ± SD from three or more independent stu3.2. NAM increases intracellular NAD+ levels in hepatocytes
Sirt1 is a NAD+-dependent deacetylase. In mammalian cells NAM is
readily converted to NAD+ through the salvage pathway. To determine
the effect of NAM supplementation on intracellular NAD contents in he-
patocytes, HepG2 cells were treated with NAM (1 and 5 mM) for 2 and
8 h, respectively, and intracellular NAD+ and NADH concentrations
were measured as previously described by us [32]. As shown in Fig. 2,
only the higher dose of NAM (5 mM) led to the signiﬁcant elevations
of intracellular NAD+ and NAD+/NADH ratio after a 2-hour NAM expo-
sure, however, theywere signiﬁcantly increased by both concentrations
of NAM at the 8-hour time point. At 5 mM, intracellular NAD+ concen-
trationwas increased by close to 60% in comparison to control cells after
an 8-hour exposure.
3.3. Cellular NAD+ increase only partially contributes to NAM-induced
Sirt1 upregulation
NAM phosphoribosyltransferase (Nampt) is the rate-limiting
enzyme in the salvage pathway for NAD+ biosynthesis from NAM,
which converts NAM to NAM mononucleotide (NMN) [33], followed
by NAD+ generation (Fig. 3A). To determine the potential mechanistic
involvement of NAD+ increment in NAM-induced Sirt1 upregulation,
HepG2 cells were pretreated with FK866, a potent inhibitor of
Nampt, for 2 h before NAM supplementation. The inclusion of
FK866 in culture media not only lowered basal intracellular NAD+
levels, but also abolished NAD+ increase in NAM-treated cells, both
being prevented by the addition of NMN (Fig. 3B), the direct precursortion. HepG2 cells were treated with NAM at 5 mM for 8 h with/without 2-h pretreatment
eaction fromNAM in the salvage pathway. A. the de novo pathway, which uses tryptophan
osynthesis. Nampt: nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of
, which is recovered by NMN supplementation. C: FK866 partially prevents NAM-induced
dies. Bars with different letters differ signiﬁcantly (p b 0.05).
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NAM-induced Sirt1 upregulation (Fig. 3C). Although NMN supplementa-
tion at 0.5 mM resulted in a similar extent of intracellular NAD+ increase
as NAM at 5 mM did (Fig. 3B), a lesser extent of increase in Sirt1 expres-
sion was induced and FK866 had no effect on NMN-induced Sirt1 upreg-
ulation (Fig. 3C).
3.4. NAM increases intracellular cAMP levels in hepatocytes via suppressing
PDE activity
Intracellular cAMP has been recently emerging as an important
factor mediating Sirt1 activity through a NAD+-independent mecha-
nism [25,26]. To determine if this can be a mechanism attributing to
NAM-mediated Sirt1 upregulation, we ﬁrst examined the effect of
NAM supplementation on intracellular cAMP level. In comparison to
control cells, bothHepG2 cells (Fig. 4A) and primarymouse hepatocytes
(Fig. 4B) exposed to NAMmanifested a dose-dependent increase of in-
tracellular cAMP levels. A signiﬁcant elevation of intracellular cAMP
levels was observed at as early as 1 h after NAM supplementation
(Fig. 4A & B). Intracellular cAMP concentration is controlled by its pro-
duction catalyzed by adenylyl cyclase (AC) and degradation by phos-
phodiesterase (PDE). Both AC activation and PDE inhibition lead to
intracellular cAMP elevation [30,31]. To delineate the mechanism in-
volved in NAM-induced cAMP increase, HepG2 cells were initially
pretreated with either SQ22536, a selective AC inhibitor, or forskolin,
an AC activator, for 2 h before NAM supplementation. While AC inhibi-
tion failed to abolish NAM-induced intracellular cAMP elevation, AC
activation by forskolin further increased intracellular cAMP level inFig. 4.NAMsupplementation increases intracellular cAMP level. BothHepG2 cells (A) and prima
Intracellular cAMP levels were determined. NAM elevates intracellular cAMP concentration in a
three or more independent studies. C. SQ22536 fails to attenuate NAM-induced cAMP elevatio
cells were treatedwith NAMwith/without a 2-h pretreatment of either SQ22536, a speciﬁc ade
cAMP concentrationwas determined. All values are denoted asmeans± SD from three ormore
presses PDE activity. HepG2 cells were treated with NAM for 2 h and intracellular PDE activity
studies. Bars with different letters differ signiﬁcantly (p b 0.05).NAM-treated cells (Fig. 4C). These results suggested that AC activity is
not involved in NAM's impact on intracellular cAMP changes. We thus
subsequently measured the effect of NAM on PDE enzymatic activity.
In comparison to control cells, a two-hour NAM exposure signiﬁcantly
lowered enzymatic activity of PDE (Fig. 4D).3.5. Activation of cAMP/PKA/CREB pathway contributes to NAM-induced
Sirt1 upregulation
The main downstream events followed by an increase of cellular
cAMP concentration include PKA phosphorylation (activation), which
subsequently phosphorylates/activates transcription factor CREB, lead-
ing to the upregulation of target genes/proteins. Interestingly, a recent
study showed that CREB controls Sirt1 expression [25,26]. To determine
whether cAMP/PKA/CREB pathway activation is mechanistically in-
volved in NAM-induced Sirt1 expression, we ﬁrst examined the effect
of NAM on PKA and CREB phosphorylation status in HepG2 cells. As
shown in Fig. 5A, both PKA and CREB was activated by NAM exposure,
manifested by a substantial increase of corresponding phosphorylated
protein abundance. Enhanced CREB phosphorylation was associated
with increased nuclear CREB protein abundance (Fig. 5B). Importantly,
NAM's effects were all dampened by the pretreatment with H89, a spe-
ciﬁc inhibitor of PKA (Fig. 5A & B). Furthermore, we blocked cAMP/PKA/
CREB pathway with either H89 pretreatment or CREB siRNA transfec-
tion, before NAM supplementation, followed by the measurement of
Sirt1 expression. Both PKA inhibition by H89 (Fig. 5C) and CREB knock-
down by siRNA transfection (Fig. 5D) abolished NAM-induced Sirt1rymouse hepatocytes (B)were treatedwithNAM(1and 5mM) for indicated timeperiods.
dose-dependentmanner. * p b 0.05 vs. control. All values are denoted asmeans± SD from
n, whereas forskolin aggravates cAMP increase induced by NAM supplementation. HepG2
nylyl cyclase (AC) inhibitor, or forskolin, a potent stimulator of AC, for 2 h and intracellular
independent studies. Barswith different letters differ signiﬁcantly (p b 0.05). D. NAM sup-
was determined. All values are denoted as means ± SD from three or more independent
Fig. 5. Activation of cAMP/PKA/CREB pathway contributes to NAM-induced Sirt1 upregulation. HepG2 cells were treated with 5 mMNAM, with or without 2-hour H89 pretreatment, for
2 h and PKA and CREB activationswere determined. A. PKA and CREB phosphorylations. B. Nuclear CREB protein abundance. C–E. Both H89 pretreatment (C) and CREB siRNA transfection
(D&E) abolishes NAM-induced Sirt1 upregulation.HepG2 cellswere treatedwith 5mMNAMwith orwithout a 2-h pretreatment ofH89, a speciﬁc PKA inhibitor, or overnight transfection
of siRNA for CREB. CREB and Sirt1 protein abundance after an 8-hour NAM treatment were determined byWestern blot. F. Sirt1 protein abundance in primarymouse hepatocytes. Mouse
primary hepatocytes were treated with NAM, with or without a 2-hour H89 pretreatment, for 8 h. Sirt1 protein abundance were determined by Western blot.
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H89 pretreatment in primary mouse hepatocytes (Fig. 5F).
3.6. NAM ameliorates palmitate-induced ER stress via a Sirt1-dependent
mechanism
Previous report demonstrated that Sirt1 activation protected hepa-
tocytes against palmitate-triggered UPR response and ER stress [12];
therefore, the Sirt1-enhancing property raised the possibility that
NAM may confer protection against palmitate-induced UPR response
and ER stress in hepatocytes. To test this possibility, we ﬁrst exposed
HepG2 cells to palmitate (conjugated to BSA at a 2:1 M ratio), with/
without a 2 hour pretreatment with NAM, for 16 h. UPR and ER stress
induction was characterized by measuring CHOP and GRP78 expres-
sions at both mRNA and protein levels, as well as protein phosphoryla-
tion of PERK and JNK, a downstream target of Ire1α activation. Palmitate
exposure dose-dependently increased CHOP and GRP78 gene expres-
sions (Fig. 6A) and protein abundance (Fig. 6B). Similarly, both PERK
and JNK phosphorylation was markedly enhanced by palmitate expo-
sure (Fig. 6C). NAM pretreatment alleviated palmitate-triggered ER
stress induction (Fig. 6A-C). To determine themechanistic involvement
of Sirt1 upregulation in NAM's beneﬁcial effect against ER stress, HepG2
cells were either pretreated with Sirtinol, a selective chemical inhibitorof Sirt1, or transfected with siRNA for Sirt1 before NAM and palmitate
exposure. The Sirt1 inhibition abrogated the ameliorative effect of
NAM on palmitate-triggered ER stress, evidenced by the recovery of
CHOP and GRP78 expressions, as well as PERK and JNK phosphorylation
(Fig. 6A-C).
4. Discussion
In the present study,we examined the effect of exogenousNAMsup-
plementation on Sirt1 expression and activity in hepatocytes and inves-
tigated underlying mechanisms behind, as well as its contribution to
NAM-conferred protection against palmitate-triggered ER stress. We
demonstrated for theﬁrst time to our knowledge thatNAM supplemen-
tation protected hepatocytes against ER stress in response to palmitate
exposure via Sirt1 upregulation. NAM supplementation led to enhanced
Sirt1 expression and enzymatic activity, concomitant with a signiﬁcant
increase of intracellular NAD+ level. Nevertheless, although Nampt in-
hibition abrogated NAM-induced NAD+ increase, it failed to abolish
Sirt1 upregulation, suggesting that intracellular NAD+ increment only
partially contributes to NAM-mediated Sirt1 upregulation. Further
mechanistic investigations unraveled that NAM supplementation led
to a signiﬁcant elevation of intracellular cAMP level, concomitant with
enhanced PKA and CREB phosphorylation/activation, the canonical
Fig. 6.NAMameliorates palmitate-triggered ER stress in hepatocytes in a Sirt1-dependent
mechanism. A & B. Gene expressions and protein abundance of CHOP and GRP78, two ER
stress markers. B. PERK and JNK activation. HepG2 cells were treated with palmitate with
or without NAM in the presence or absence of Sirtinol, a selective Sirt1 inhibitor, or of
overnight siRNA transfection for 16 h. CHOP and GRP78 expressions were determined
by qRT-PCR and Western blot, respectively. P-PERK, p-JNK, PERK, and JNK proteins were
detected byWestern blot. All values are denoted asmeans± SD from three ormore inde-
pendent studies. Barswith different letters differ signiﬁcantlywithin same gene (p b 0.05).
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portantly, we found that the blockade of this pathway abolished not
only NAM-induced Sirt1 upregulation, but also NAM's protection
against palmitate-triggered ER stress, suggesting that the cAMP/PKA/
CREB pathway activation plays a mechanistic role in this event.
NAM is the amide of nicotinic acid (vitamin B3/niacin). As the pre-
dominant precursor for cellular NAD+ biosynthesis via the salvage
pathway [4,5], NAM supplementation has been reported to increase
Sirt1 activity in a variety of cell types [30,31] and protected immune
cells against stress-triggered cell death [34]. Paradoxically, as NAM is
the common product of Sirt1-mediated deacetylation reactions, it is
also a widely employed as a chemical inhibitor of Sirt1 [27–29]. The
factors leading to these conﬂicted observations may derive from cell
type, dosage, and exposure duration, and remain to be clariﬁed. In this
study, we clearly demonstrated that NAM at less than 5 mM upregulat-
ed Sirt1 expression and activity in hepatocytes, which plays amechanistic role in the protective effect of NAM against palmitate-
triggered ER stress.
Although it is currently not clear as to how the catalytic activity of
Sirt1 is precisely regulated, several previous studies have demonstrated
that changes in intracellular NAD+ levels are sufﬁcient to alter Sirt1 activ-
ity under a variety of conditions [15–24]. In the current study, the robust
increases of intracellular NAD+ levels were observed when hepatocytes
were treated with NAM. Moreover, the NAM-induced NAD+ elevation
was abolished by Nampt inhibition, indicating that exogenous NAM sup-
plementation enhances NAD+ biosynthesis via the salvage pathway. It
was in fact our initial hypothesis that NAM induces Sirt1 upregulation
via this canonical mechanism. We indeed showed that NMN, a direct
precursor for NAD+ biosynthesis, upregulated Sirt1 expression and
protected hepatocytes against palmitate-induced ER stress (Supplemen-
tary Fig. S1). However, the hypothesis was not fully supported by our
observations in that Sirt1 expression remained to be upregulated in re-
sponse to NAM addition under the circumstance of the salvage pathway
blockage by Nampt inhibitor, although which completely abrogated
NAM-induced intracellular NAD+ increase. These results altogether sug-
gest that a NAD+-independent mechanism exits for NAM-induced Sirt1
upregulation.
Emerging evidence supports that the activation of the cAMP/PKA/
CREB pathway controls Sirt1 expression and activation independently
of changes in intracellular NAD+ levels [24,25]. In the present study,
we examined the potential mechanistic involvement of this pathway
in NAM-induced Sirt1 upregulation. Our study revealed for the ﬁrst
time that NAM supplementation elevated intracellular cAMP concentra-
tion in hepatocytes and activated cAMP/PKA/CREB signaling pathway.
Whereas Nampt inhibition by FK866 failed to abrogate NAM-induced
Sirt1 upregulation and protection against palmitate-triggered ER stress,
both PKA inhibitor and CREB gene knockdown via siRNA transfection
abolished NAM's beneﬁcial effects (Supplementary Fig. S2), indicating
that the cAMP/PKA/CREB pathway activation plays a mechanistic role
in the regulation of NAM-induced Sirt1 upregulation and resultant pro-
tection against ER stress. As mentioned previously, intracellular cAMP
concentration is controlled by its production catalyzed by adenylyl cy-
clase (AC) and degradation, which is catalyzed by phosphodiesterase
(PDE), and both AC activation and PDE inhibition lead to intracellular
cAMP elevation [35,36]. In an effort to identify the potential mechanism
involved in the enhancing effect of NAM on cellular cAMP concentration,
both activator (forskolin) and inhibitor (SQ22536) of ACwas utilized. The
observations that AC inhibition failed to abolish NAM-induced intracellu-
lar cAMP elevation while AC activation aggravates intracellular cAMP ac-
cumulation in NAM-treated cells indicated that the enzyme is not the key
regulatory point for NAM. The direct measurement of PDE activity con-
ﬁrmed that NAM suppressed PDE activity. This observation is indeed in
line with a previous report in which NAM was used as a PDE inhibitor
[37].
In summary, our data demonstrate that, in hepatocytes, NAM supple-
mentation protects hepatocytes against palmitate-triggered ER stress via
Sirt1 upregulation. Both NAD+-dependent and –independent mecha-
nisms are involved in NAM-induced Sirt1 activation in hepatocytes. Our
results suggest that the activation of cAMP/PKA/CREB pathway via sup-
pression PDE activity plays a critical role in NAM's stimulatory effect on
Sirt1. These results support that NAM can confer protection against
lipotoxicity via acting as either a NAD+ booster or a Sirt1 activator. Fur-
ther investigations are required to test the potential therapeutic function
of NAM in liver diseases with either NAD+ depletion or Sirt1 suppression
being a pathological factor.Acknowledgments
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